Literature DB >> 28876968

Corneal Collagen Cross-Linking Complications.

Charisma B Evangelista1, Kathryn M Hatch2.   

Abstract

Corneal cross-linking was approved by United States Food and Drug Administration for the treatment of progressive keratoconus in April 2016. As this approach becomes more widely used for the treatment of keratoconus and post-laser in situ keratomileusis (LASIK) ectasia, the medical community is becoming more familiar with potential complications associated with this procedure. This article aims to review the reported complications of collagen cross-linking for the treatment of keratoconus and post-LASIK ectasia.

Entities:  

Keywords:  Ectasia; epi-off; epi-on; keratoconus (KCN); post-LASIK ectasia; transepithelial cross-linking (TE CXL)

Mesh：

Substances：

Year:  2017        PMID： 28876968     DOI： 10.1080/08820538.2017.1353809

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN： 0882-0538            Impact factor:   1.975


  12 in total

1.  Complications of accelerated corneal collagen cross-linking: review of 2025 eyes.

Authors:  Semih Çakmak; Mehmet Emin Sucu; Yusuf Yildirim; Burcin Kepez Yildiz; Ahmet Kirgiz; Damla Leman Bektaşoğlu; Ahmet Demirok
Journal:  Int Ophthalmol       Date:  2020-07-26       Impact factor: 2.031

2.  Hypertension secondary to nitric oxide depletion produces oxidative imbalance and inflammatory/fibrotic outcomes in the cornea of C57BL/6 mice.

Authors:  Álvaro Santana-Garrido; Claudia Reyes-Goya; Ana Arroyo-Barrios; Helder André; Carmen M Vázquez; Alfonso Mate
Journal:  J Physiol Biochem       Date:  2022-08-09       Impact factor: 5.080

3.  Comment on: "What are the costs, capacity, and clinical implications of "waiting for documented progression" in young West of Scotland patients prior to collagen cross linking?"

Authors:  David O'Brart; Mehran Zarei-Ghanavati; Alfonso Vasquez-Perez; Christopher Liu
Journal:  Eye (Lond)       Date:  2021-08-18       Impact factor: 4.456

4.  In vivo Assessment of Localised Corneal Biomechanical Deterioration With Keratoconus Progression.

Authors:  Bernardo T Lopes; Prema Padmanabhan; Ashkan Eliasy; Haixia Zhang; Ahmed Abass; Ahmed Elsheikh
Journal:  Front Bioeng Biotechnol       Date:  2022-06-08

5.  Quantitative Assessment of Biomechanical Properties of the Human Keratoconus Cornea Using Acoustic Radiation Force Optical Coherence Elastography.

Authors:  Yanzhi Zhao; Hongwei Yang; Yingjie Li; Yongbo Wang; Xiao Han; Yirui Zhu; Yubao Zhang; Guofu Huang
Journal:  Transl Vis Sci Technol       Date:  2022-06-01       Impact factor: 3.048

6.  Infectious keratitis after corneal crosslinking: systematic review.

Authors:  Caroline E Murchison; W Matthew Petroll; Danielle M Robertson
Journal:  J Cataract Refract Surg       Date:  2021-08-01       Impact factor: 3.528

7.  Intrastromal Injection of Hyaluronidase Alters the Structural and Biomechanical Properties of the Corneal Stroma.

Authors:  Soohyun Kim; Iman Jalilian; Sara M Thomasy; Morgan A W Bowman; Vijay Krishna Raghunathan; Yeonju Song; Cynthia A Reinhart-King; Christopher J Murphy
Journal:  Transl Vis Sci Technol       Date:  2020-05-21       Impact factor: 3.283

8.  Three-year results of accelerated transepithelial cross-linking (30 mW/cm2 × 3 min) for keratoconus: a prospective study.

Authors:  Hitoha Ishii; Junko Yoshida; Tetsuya Toyono; Satoru Yamagami; Tomohiko Usui; Takashi Miyai
Journal:  BMJ Open Ophthalmol       Date:  2022-02-08

Review 9.  Corneal Cross-Linking: The Evolution of Treatment for Corneal Diseases.

Authors:  Duoduo Wu; Dawn Ka-Ann Lim; Blanche Xiao Hong Lim; Nathan Wong; Farhad Hafezi; Ray Manotosh; Chris Hong Long Lim
Journal:  Front Pharmacol       Date:  2021-07-19       Impact factor: 5.810

10.  Safety and efficacy of repeated crosslinking assisted by transepithelial double-cycle iontophoresis in keratoconus progression after primary corneal crosslinking.

Authors:  Huping Wu; Lan Li; Shunrong Luo; Xie Fang; Xumin Shang; Zhiwen Xie; Xianwen Xiao; Huan He; Zhirong Lin; Zuguo Liu
Journal:  Eye (Lond)       Date:  2021-01-07       Impact factor: 4.456
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.